Tetralogy of Fallow: Four Trials and Tribulations

JACC: Heart Failure

Volumn 5, Issue 6, 2017, Pages 408-410

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

clinical trials; flosequinan; tetralogy; vasodilators

Indexed keywords

AMLODIPINE; BOSENTAN; FLOSEQUINAN; LEVOSIMENDAN; VASODILATOR AGENT;

DRUG EFFICACY; EDITORIAL; HEART FAILURE; HUMAN; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; DRUG EFFECT; HEMODYNAMICS;

HEART FAILURE; HEMODYNAMICS; HUMANS; VASODILATOR AGENTS;

EID: 85019138480     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.03.004     Document Type: Editorial

References (15)

1. O'Connor, C., Dead letter office. J Am Coll Cardiol HF 1 (2013), 181–182.
2. Packer, M., Colucci, W., Fisher, L., et al., REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol HF 1 (2013), 103–111.
3. Packer, M., Carson, P., Elkayam, U., et al., PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). J Am Coll Cardiol HF 1 (2013), 308–314.
4. Packer, M., McMurray, J.J.V., Swedberg, K., et al., ENABLE Investigators and Committees. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. J Am Coll Cardiol HF 5 (2017), 317–326.
5. Packer, M., Pitt, B., Rouleau, J.-L., Swedberg, K., DeMets, D.L., Fisher, L., Long-term effects of flosequinan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the PROFILE trial after 24 years. J Am Coll Cardiol HF 5 (2017), 399–407.
6. Califf, R.M., Better late than never: a welcome publication of tardy clinical trial results. J Am Coll Cardiol HF 1 (2013), 112–114.
7. Pfeffer, M.A., Skali, H., PRAISE (prospective randomized amlodipine survival evaluation) and criticism. J Am Coll Cardiol HF 1 (2013), 315–317.
8. Packer, M., Unbelievable folly of clinical trials in heart failure: the inconvenient truth about how investigators and guidelines weigh evidence. Circ Heart Fail, 9, 2016, e002837.
9. Packer, M., Love of angiotensin-converting enzyme inhibitors in the time of cholera. J Am Coll Cardiol HF 4 (2016), 403–408.
10. Packer, M., The room where it happens: a skeptic's analysis of the new heart failure guidelines. J Card Fail 22 (2016), 726–730.
11. Packer, M., Heart failure's dark secret: does anyone really care about optimal medical therapy?. Circulation 134 (2016), 629–631.
12. Moe, G.W., Rouleau, J.L., Charbonneau, L., et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am Heart J 139 (2000), 587–595.
13. Hansen, M.S., Stanton, E.B., Gawad, Y., et al., Canadian PROFILE Investigators. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol 90 (2002), 969–973.
14. Stanton, E.B., Hansen, M.S., Sole, M.J., et al., PROFILE Investigators. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Can J Cardiol 21 (2005), 39–43.
15. van Veldhuisen, D.J., Poole-Wilson, P.A., The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failure. Int J Cardiol 80 (2001), 19–27.